{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:40:47Z","timestamp":1783766447507,"version":"3.55.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.amjopharm.2010.08.002","type":"journal-article","created":{"date-parts":[[2010,9,25]],"date-time":"2010-09-25T04:43:58Z","timestamp":1285389838000},"page":"294-315","source":"Crossref","is-referenced-by-count":58,"title":["Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease"],"prefix":"10.1016","volume":"8","author":[{"given":"Lindy D.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Setter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Dobbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2010.08.002_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jns.2007.08.015","article-title":"Management of non-motor symptoms in advanced Parkinson disease","volume":"266","author":"Truong","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib2","series-title":"An Essay on the Shaking Palsy","author":"Parkinson","year":"1817"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2010.08.002_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","article-title":"Non-motor symptoms in Parkinson's disease","volume":"15","author":"Poewe","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000109757","article-title":"Olfactory dysfunction in Parkinson's disease","volume":"16","author":"Kranic","year":"2008","journal-title":"Neurosignals"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-3-211-45295-0_48","article-title":"Detection of preclinical Parkinson's disease along the olfactory trac(t)","volume":"70","author":"Berendse","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1212\/01.wnl.0000340980.19702.6e","article-title":"Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder","volume":"72","author":"Postuma","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.amjmed.2009.01.025","article-title":"Pharmacological management of psychosis in elderly patients with parkinsonism","volume":"122","author":"Hasnain","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2377-9-23","article-title":"Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: A case-control study","volume":"9","author":"Ecker","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.22453","article-title":"Psychotic and compulsive symptoms in Parkinson's disease","volume":"24","author":"Verbaan","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib14","series-title":"Parkinson's Disease: Diagnosis and Clinical Management","first-page":"593","article-title":"Psychosis and other behaviors","author":"Molho","year":"2008"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","article-title":"Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial","volume":"16","author":"Factor","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00002826-200301000-00003","article-title":"Clozapine in Parkinson's disease psychosis: 5-Year follow-up review","volume":"26","author":"Klein","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: A randomized, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: A review","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Mov Disord"},{"issue":"Suppl 5","key":"10.1016\/j.amjopharm.2010.08.002_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00406-008-5012-4","article-title":"Psychiatric symptoms in Parkinson's disease","volume":"258","author":"Schneider","year":"2008","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","article-title":"Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis","volume":"17","author":"Frieling","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 6","key":"10.1016\/j.amjopharm.2010.08.002_bib22","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1002\/mds.10567","article-title":"Psychosis in Parkinson's disease","volume":"18","author":"Poewe","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis [published correction appears in Clin Neuropharmacol. 2004;27:256]","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0733-8627(05)70122-X","article-title":"Psychosis","volume":"18","author":"Richards","year":"2000","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00023210-199911060-00005","article-title":"The role of atypical antipsychotics in the treatment of movement disorders","volume":"11","author":"Fernandez","year":"1999","journal-title":"CNS Drugs"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib27","series-title":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.parkreldis.2006.12.014","article-title":"Non-motor dysfunction in Parkinson's disease","volume":"13","author":"Ziemssen","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1017\/S1041610208008600","article-title":"Dementia with Lewy bodies and Parkinson's disease dementia may best be viewed as two distinct entities","volume":"21","author":"Revuelta","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib30","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","article-title":"Cognitive profile of patients with newly diagnosed Parkinson disease","volume":"65","author":"Muslimovic","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","article-title":"Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest study","volume":"72","author":"Aarsland","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study [published correction appears in J Neurol Neurosurg Psychiatry. 2002;73:354]","volume":"72","author":"Aarsland","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 3","key":"10.1016\/j.amjopharm.2010.08.002_bib34","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/S1353-8020(08)70049-X","article-title":"Treatment of dementia associated with Parkinson's disease","volume":"13","author":"Emre","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1474-4422(03)00351-X","article-title":"Dementia associated with Parkinson's disease","volume":"2","author":"Emre","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.002_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1005256122649","article-title":"Memory impairment in Parkinson's disease","volume":"31","author":"Zakharov","year":"2001","journal-title":"Neurosci Behav Physiol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib37","series-title":"Parkinson's Disease: Diagnosis and Clinical Management","first-page":"147","article-title":"Dementia","author":"Marder","year":"2008"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/mds.20216","article-title":"Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom","volume":"19","author":"Hobson","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson's disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00415-008-0720-2","article-title":"Cognitive impairment in 873 patients with idiopathic Parkinson's disease: Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)","volume":"255","author":"Riedel","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson's disease: A community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","article-title":"A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender","volume":"49","author":"Mayeux","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib43","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","article-title":"Dementia and survival in Parkinson disease: A 12-year population study","volume":"70","author":"Buter","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/00002512-200623100-00004","article-title":"Management of Parkinson's disease dementia: Practical considerations","volume":"23","author":"Rongve","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib45","series-title":"Principles and Practice of Movement Disorders","first-page":"193","article-title":"Nonmotor problems in Parkinson's disease","author":"Fahn","year":"2007"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib46","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/mds.22087","article-title":"Cognitive dysfunction in Nigerians with Parkinson's disease","volume":"23","author":"Akinyemi","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","article-title":"Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease","volume":"107","author":"Giladi","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00002826-200011000-00006","article-title":"Cognitive and motor function in patients with Parkinson's disease with and without depression","volume":"23","author":"Cubo","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1176\/appi.neuropsych.14.1.31","article-title":"Effects of depression and Parkinson's disease on cognitive functioning","volume":"14","author":"Norman","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s004150050104","article-title":"A study of visual hallucinations in patients with Parkinson's disease","volume":"244","author":"Klein","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib51","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1532-5415.1996.tb00918.x","article-title":"Psychotic symptoms in Parkinson's disease patients with dementia","volume":"44","author":"Naimark","year":"1996","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archneur.1997.00550150024011","article-title":"Mortality from Parkinson disease","volume":"54","author":"Louis","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib53","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/01.WNL.0000036610.36834.E0","article-title":"The association of incident dementia with mortality in PD","volume":"59","author":"Levy","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000197892","article-title":"Pharmacotherapy of Parkinson disease and dementia and Lewy body dementia","volume":"24","author":"Gauthier","year":"2009","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebocontrolled trial of donepezil in cognitive impairment in Parkinson's disease","volume":"19","author":"Leroi","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib56","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-211-33328-0_3","article-title":"The DONPAD-study\u2014treatment of dementia in patients with Parkinson's disease with donepezil","volume":"71","author":"M\u00fcller","year":"2006","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","article-title":"Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia","volume":"18","author":"Aarsland","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib59","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","article-title":"Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)","volume":"38","author":"Litvinenko","year":"2008","journal-title":"Neurosci Behav Physiol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib60","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1034\/j.1600-0404.2003.00211.x","article-title":"Rivastigmine (Exelon) for dementia in patients with Parkinson's disease","volume":"108","author":"Giladi","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib61","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib62","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/mds.20700","article-title":"Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study","volume":"21","author":"Poewe","year":"2006","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.amjopharm.2010.08.002_bib64","first-page":"CD004747","article-title":"Cholinesterase inhibitors for Parkinson's disease dementia","author":"Maidment","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.amjopharm.2010.08.002_bib65","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib66","series-title":"Aricept [package insert]","year":"2005"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib67","series-title":"Exelon [package insert]","year":"2006"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib68","series-title":"Exelon patch [package insert]","year":"2009"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib69","series-title":"Razadyne\/Razadyne ER [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.002_bib71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1176\/appi.neuropsych.13.2.187","article-title":"Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease","volume":"13","author":"Slaughter","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib72","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/mds.10387","article-title":"Higher incidence of depression preceding the onset of Parkinson's disease: A register study","volume":"18","author":"Leentjens","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archneur.1996.00550020087019","article-title":"The occurrence of depression in Parkinson's disease. A community-based study","volume":"53","author":"Tandberg","year":"1996","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00536.x","article-title":"Depression in Parkinson's disease\u2014a review","volume":"113","author":"Lieberman","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jns.2009.08.016","article-title":"Suicide and suicidal ideation in Parkinson's disease","volume":"289","author":"Kostic","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib76","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","article-title":"A survey of antidepressant drug use in Parkinson's disease","volume":"49","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib77","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib78","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/jnp.7.3.281","article-title":"Treatment of depression in Parkinson's disease: A meta-analysis","volume":"7","author":"Klaassen","year":"1995","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib79","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.149.4.443","article-title":"Depression and Parkinson's disease: A review","volume":"149","author":"Cummings","year":"1992","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib80","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.disamonth.2007.02.004","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"53","author":"Dubow","year":"2007","journal-title":"Dis Mon"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1531-8257(199901)14:1<155::AID-MDS1026>3.0.CO;2-Z","article-title":"Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series","volume":"14","author":"Richard","year":"1999","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2010.08.002_bib82","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/BF03160564","article-title":"Sleep disorder related to Parkinson's disease","volume":"244","author":"Partinen","year":"1997","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib83","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mds.870130606","article-title":"A community-based study of sleep disorders in patients with Parkinson's disease","volume":"13","author":"Tandberg","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/01.WNL.0000073619.94467.B0","article-title":"Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism","volume":"61","author":"Boeve","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib85","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1212\/WNL.59.4.585","article-title":"REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease","volume":"59","author":"Gagnon","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.parkreldis.2008.02.002","article-title":"Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease","volume":"15","author":"Suzuki","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib87","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.287.4.455","article-title":"Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group","volume":"287","author":"Hobson","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib88","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/mds.870050404","article-title":"Sleep disorders and sleep effect in Parkinson's disease","volume":"5","author":"Factor","year":"1990","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib89","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.amjopharm.2010.08.002_bib90","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.63.8_suppl_3.S24","article-title":"Excessive daytime sleepiness in Parkinson's disease","volume":"63","author":"Schapira","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib91","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/mds.10417","article-title":"Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease","volume":"18","author":"Paus","year":"2003","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"10.1016\/j.amjopharm.2010.08.002_bib92","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1007\/s10072-007-0732-1","article-title":"Daytime somnolence and night sleep disturbances in Parkinson's disease: Background and future treatment prospective","volume":"28","author":"Antonini","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib93","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/brain\/awh079","article-title":"Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome","volume":"127","author":"Stiasny-Kolster","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib94","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.51.2.526","article-title":"Sleep-related violence, injury and REM sleep behavior disorder in Parkinson's disease","volume":"51","author":"Comella","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib95","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1176\/ajp.146.9.1166","article-title":"A polysomnographic and clinical report on sleep-related injury in 100 adult patients","volume":"146","author":"Schenck","year":"1989","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib96","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/archneur.59.3.421","article-title":"Exploring the relationship between Parkinson disease and restless legs syndrome","volume":"59","author":"Ondo","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mds.10307","article-title":"Restless legs syndrome in Parkinson's disease: A case-controlled study","volume":"18","author":"Krishnan","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00002018-199819010-00002","article-title":"Safety of selegiline (deprenyl) in the treatment of Parkinson's disease","volume":"19","author":"Heinonen","year":"1998","journal-title":"Drug Saf"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib99","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00455-008-9180-1","article-title":"Effects of therapy for dysphagia in Parkinson's disease: A systematic review","volume":"24","author":"Baijens","year":"2009","journal-title":"Dysphagia"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/gast.1996.v110.pm8566584","article-title":"Mechanisms of oral pharyngeal dysphagia in patients with Parkinson's disease","volume":"110","author":"Ali","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib101","first-page":"1010","article-title":"Relationship between weight loss and dysphagia in patients with Parkinson's disease [in Japanese]","volume":"39","author":"Nozaki","year":"1999","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib102","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000112902","article-title":"Dysphagia in Parkinson's disease","volume":"38","author":"Coates","year":"1997","journal-title":"Eur Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib103","first-page":"1741","article-title":"Swallowing and esophageal function in Parkinson's disease","volume":"90","author":"Johnston","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib104","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ageing\/afl105","article-title":"Hard to swallow: Dysphagia in Parkinson's disease","volume":"35","author":"Miller","year":"2006","journal-title":"Age Ageing"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clineuro.2007.09.011","article-title":"Silent aspiration in Parkinson's disease patients with diurnal sialorrhea","volume":"110","author":"Nobrega","year":"2008","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.TGR.0000318899.87690.44","article-title":"Speech and swallowing in Parkinson's disease","volume":"24","author":"Tjaden","year":"2008","journal-title":"Top Geriatr Rehabil"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib107","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/mds.22617","article-title":"The relationship between quality of life and swallowing in Parkinson's disease","volume":"24","author":"Plowman-Prine","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib108","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archneur.57.4.507","article-title":"Parkinson disease survival: A population-based study","volume":"57","author":"Morgante","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib109","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mds.10537","article-title":"Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: A 9-year follow-up","volume":"18","author":"Fall","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-005-0916-7","article-title":"Long-term survival of Parkinson's disease: A population-based study","volume":"253","author":"D'Amelio","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib111","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-0404.2001.00191.x","article-title":"Causes of death in a community-based study of Parkinson's disease","volume":"103","author":"Beyer","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib112","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0303-8467(97)00606-9","article-title":"Swallowing difficulty in Parkinson's disease","volume":"99","author":"Fuh","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib113","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00455-007-9113-4","article-title":"The coordination of breathing and swallowing in Parkinson's disease","volume":"23","author":"Gross","year":"2008","journal-title":"Dysphagia"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/PL00009512","article-title":"Pharyngo-esophageal dysphagia in Parkinson's disease","volume":"12","author":"Leopold","year":"1997","journal-title":"Dysphagia"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib115","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/jnnp.2008.157701","article-title":"Swallowing problems in Parkinson's disease: Frequency and clinical correlates","volume":"80","author":"Miller","year":"2009","journal-title":"J Neurol Neurosurg"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib116","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1353-8020(03)00045-2","article-title":"Swallowing disorders in Parkinson's disease","volume":"9","author":"Potulska","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib117","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MOO.0b013e3282febd3a","article-title":"Speech and swallowing disorders in Parkinson disease","volume":"16","author":"Sapir","year":"2008","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0404.1998.tb00605.x","article-title":"Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease","volume":"97","author":"Clarke","year":"1998","journal-title":"Acta Neurol Scan"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib119","first-page":"11","article-title":"Effect of swallowing training on swallowing disorders in Parkinson's disease","volume":"32","author":"Nagaya","year":"2000","journal-title":"Scand JRehabilMed"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib120","first-page":"213","article-title":"A study of salivary secretion in Parkinson's disease","volume":"22","author":"Bagheri","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib122","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease","volume":"62","author":"Ondo","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib123","first-page":"153","article-title":"Cardiovascular autonomic function in parkinsonian patients","volume":"5","author":"Mathias","year":"1998","journal-title":"Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib124","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(03)00555-6","article-title":"Dysautonomia in Parkinson's disease: Neurocardiological abnormalities [published correction appears in Lancet Neurol. 2004;3:68]","volume":"2","author":"Goldstein","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.amjopharm.2010.08.002_bib125","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/WNL.53.5.1020","article-title":"Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy","volume":"53","author":"Braune","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib126","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease","volume":"63","author":"Senard","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib127","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.autneu.2004.06.009","article-title":"Impaired cardiovascular autonomic control in newly and long-termtreated patients with Parkinson's disease: Involvement of L-dopa therapy","volume":"116","author":"Bouhaddi","year":"2004","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib128","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00415-003-1029-9","article-title":"Autonomic dysfunctions in dementia with Lewy bodies","volume":"250","author":"Horimoto","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib129","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00002512-200118070-00003","article-title":"Orthostatic hypotension in patients with Parkinson's disease: Pathophysiology and management","volume":"18","author":"Senard","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/jnnp.23.4.283","article-title":"The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans","volume":"23","author":"den Hartog Jager","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib131","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00002512-199710040-00002","article-title":"Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management","volume":"10","author":"Jost","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib132","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"2","author":"Pfeiffer","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib133","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imj.1965.14.1.13","article-title":"Alimentary disorder in parkinsonism","volume":"14","author":"Eady","year":"1965","journal-title":"Australas Ann Med"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib134","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/mds.870080115","article-title":"Gastro -intestinal symptoms in Parkinson disease: 18-Month follow-up study","volume":"8","author":"Edwards","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib135","first-page":"463","article-title":"Autonomic nervous system disturbances in Parkinson's disease","volume":"53","author":"Korczyn","year":"1990","journal-title":"Adv Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib136","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.57.3.456","article-title":"Frequency of bowel movements and the future risk of Parkinson's disease","volume":"57","author":"Abbott","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/1531-8257(200001)15:1<71::AID-MDS1012>3.0.CO;2-W","article-title":"Anorectal function in MSA and Parkinson's disease","volume":"15","author":"Stocchi","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib138","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archneur.1989.00520460037010","article-title":"Anal sphincter dysfunction in Parkinson's disease","volume":"46","author":"Mathers","year":"1989","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib139","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0022-5347(05)67048-6","article-title":"Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms","volume":"164","author":"Araki","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.urology.2005.10.017","article-title":"Erectile dysfunction in Parkinson's disease","volume":"67","author":"Papatsoris","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib141","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0404.1995.tb00445.x","article-title":"Sexual problems in young patients with Parkinson's disease","volume":"91","author":"Wermuth","year":"1995","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib142","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1531-8257(200003)15:2<305::AID-MDS1015>3.0.CO;2-W","article-title":"Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease","volume":"15","author":"Zesiewicz","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib143","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0302-2838(02)00054-4","article-title":"Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease","volume":"41","author":"Raffaele","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib144","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archneur.1971.00480310078007","article-title":"Autonomic deficits in Parkinson's syndrome","volume":"24","author":"Appenzeller","year":"1971","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib145","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00920619","article-title":"Sweat function in Parkinson's disease","volume":"241","author":"Mano","year":"1994","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/WNL.36.1.73","article-title":"Autonomic dysfunction in Parkinson's disease","volume":"36","author":"Goetz","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib147","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-0404.1992.tb04043.x","article-title":"Involvement of peripheral nervous system in juvenile Parkinson's disease","volume":"85","author":"Taly","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.002_bib148","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.410370124","article-title":"Drenching sweats as an off phenomenon in Parkinson's disease: Treatment and relation to plasma levodopa profile","volume":"37","author":"Sage","year":"1995","journal-title":"Ann Neurol"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594610000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594610000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:39:27Z","timestamp":1559687967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594610000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1543594610000668"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2010.08.002","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}